[Federal Register Volume 63, Number 42 (Wednesday, March 4, 1998)] [Notices] [Pages 10638-10640] From the Federal Register Online via the Government Publishing Office [www.gpo.gov] [FR Doc No: 98-5520] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. 97N-0517] Medical Devices; Device Tracking; New Orders to Manufacturers AGENCY: Food and Drug Administration, HHS. ACTION: Notice. ----------------------------------------------------------------------- SUMMARY: The Food and Drug Administration (FDA) is announcing that the agency has issued new orders to manufacturers of devices that were subject to tracking. These new orders became effective on February 19, 1998, and require manufacturers to continue tracking the devices under the revised tracking provisions of the recently enacted Food and Drug Administration Modernization Act of 1997 (FDAMA). FDAMA allows the agency discretion in issuing orders to manufacturers to track devices that meet certain criteria. FDA is soliciting comments on what factors should be considered in exercising its discretion in determining whether the agency should not track a particular device, even though it meets the statutory criteria. FDA specifically is requesting comments on whether there are factors that FDA should consider in exercising its discretion in releasing certain devices listed in this notice from tracking requirements. Elsewhere in this issue of the Federal Register, FDA is announcing the availability of a guidance that addresses device tracking under FDAMA, including the application of certain requirements under the current tracking regulations. DATES: Written comments concerning this notice may be received by May 4, 1998. ADDRESSES: Written comments may be submitted to the Dockets Management Branch (HFA-305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857. FOR FURTHER INFORMATION CONTACT: Casper E. Uldriks, Center for Devices and Radiological Health (HFZ-300), Food and Drug Administration, 2098 Gaither Rd., Rockville, MD 20850, 301-594-4692. SUPPLEMENTARY INFORMATION: I. Background The Safe Medical Device Act of 1990 (the SMDA) added tracking provisions to the Federal Food, Drug, and Cosmetic Act (the act) by adding new section 519(e) of the act (21 U.S.C. 360i(e)). As added by the SMDA, section 519(e)(1) of the act required the adoption of a method of tracking, even if FDA did not issue an order. Specifically, any person registered under section 510 of the act (21 U.S.C. 360), and engaged in the manufacture of a device, had to track the device if the failure of that device would be reasonably likely to have serious adverse health consequences, and the device was either a permanently implantable device or a life sustaining or life supporting device used outside a device user facility. Section 519(e)(2) of the act also authorized FDA to ``designate'' other devices that must be tracked. FDA issued regulations implementing tracking requirements in the Federal Register of August 16, 1993 (58 FR 43442). The regulations became effective on August 29, 1993, and are codified in part 821 (21 CFR part 821). Under tracking provisions established by the SMDA, manufacturers had the responsibility to identify devices that met the statutory criteria for tracking. For illustrative purposes, the agency set out in Sec. 821.20(b)(1) and (b)(2) a list of example devices it considered subject to mandatory tracking under section 519(e)(1) of the act. Devices designated for tracking by FDA under section 519(e)(2) of the act were listed in Sec. 821.20(c). FDAMA was enacted on November 21, 1997. Section 211 of FDAMA amended section 519(e)(1) of the act to authorize FDA, in its discretion, to issue orders that require a manufacturer to track a class II or class III device if the failure of the device would be reasonably likely to have serious adverse health consequences, or the device is intended to be implanted in the human body for more than 1 year, or is life sustaining or life supporting and used outside a device user facility. Section 519(e)(2) of the act, as amended by FDAMA, provides that patients receiving a tracked device may refuse to provide their name, address, social security number, or other identifying information, for tracking purposes. Accordingly, tracking may be required [[Page 10639]] under section 519(e), as amended by FDAMA, only if FDA issues an order and only if the criteria described previously are met. FDAMA tracking provisions became effective on February 19, 1998. II. Implementation of FDAMA Tracking Authority FDA has initiated the measures identified in section II of this document to implement the tracking authority given to the agency under section 519(e) of the act, as amended by FDAMA. A. Manufacturer Notification/Public Meeting On December 19, 1997, FDA sent letters to manufacturers identified as having responsibilities to track devices under section 519(e) of the act. These letters advised the firms that FDAMA would implement important statutory changes in these areas and that FDA had announced in the Federal Register of December 18, 1997 (62 FR 66373), that it would conduct a public meeting on January 15, 1998, to discuss such changes. The letter also advised that existing device tracking requirements imposed by previously issued FDA regulations or FDA orders would remain in effect, until FDA notified a firm of any changes in its responsibilities. At the January 15, 1998, public meeting held in Rockville, MD, written and oral comments were received from consumer groups, clinicians, manufacturers and device industry associations. These comments ranged from considering clinical management issues, and the use of alternative tracking mechanisms, to considering the likelihood of device failure. B. Issuance of Tracking Orders On February 11, 1998, FDA issued orders to manufacturers who would be required to track their devices under section 519(e), as revised by FDAMA. These orders became effective on February 19, 1998. The devices subject to these new orders are the types of devices currently identified in the agency's tracking regulations at 21 CFR 821.20(b)(1), (b)(2), and (c), except that arterial stents and intraocular lenses have been added. FDA has determined that these devices meet the criteria under revised section 519(e) of the act. These devices are as follows: Table 1.--Devices Meeting the Criteria Under Revised Section 519(e) of the Act ------------------------------------------------------------------------ 21 CFR Section Classification ------------------------------------------------------------------------ 870.3450 Vascular graft prosthesis of less than 6 millimeters diameter 870.3460 Vascular graft prosthesis of 6 millimeters and greater diameter (no cite) Total temporomandibular joint prosthesis (no cite) Glenoid fossa prosthesis (no cite) Mandibular condyle prosthesis (no cite) Interarticular disc prosthesis (interpositional implant) 870.3545 Ventricular bypass (assist) device 870.3610 Implantable pacemaker pulse generator 870.3680(b) Cardiovascular permanent pacemaker electrode 870.3800 Annuloplasty ring 870.3925 Replacement heart valve (no cite) Automatic implantable cardioverter/defibrillator 878.3720 Tracheal prosthesis 882.5820 Implanted cerebellar stimulator 882.5830 Implanted diaphragmatic/phrenic nerve stimulator (no cite) Implantable infusion pumps (no cite) Arterial stents (used in coronary arteries or peripheral arteries) 886.3600 Intraocular lens 868.2375 Breathing frequency monitors (apnea monitors) (including ventilatory efforts monitors) 868.5895 Continuous ventilator 870.5300 DC-defribrillator and paddles 876.3350 Penile inflatable implant 878.3530 Silicone inflatable breast prosthesis 878.3540 Silicone gel-filled breast prosthesis 876.3750 Testicular prosthesis, silicone gel-filled (no cite) Silicone gel-filled chin prosthesis (no cite) Silicone gel-filled angel chik reflux valve 880.5725 Infusion pump ------------------------------------------------------------------------ C. FDA Review/Reconsideration of Devices Requiring Tracking Although FDA has issued orders to subject all of the devices described previously to tracking requirements under section 519(e) of the act, as revised by FDAMA, FDA recognizes that the new law provides the agency with discretion to not require tracking of devices that meet the statutory criteria. FDA believes that certain factors may indicate that tracking for some devices, even though they meet the statutory criteria under section 519(e) of the act, may not be necessary to protect the public health. Accordingly, FDA is soliciting comments on what factors FDA should consider in exercising its discretion to require, or not to require, tracking of those devices that meet the statutory criteria stated in section 519(e) of the act. Comments should not merely identify what devices that meet the statutory tracking criteria should or should not be tracked, but should fully address the factors that should be relevant in the agency's exercise of discretion. After reviewing the comments received in response to this document, FDA will determine what factors should be considered in exercising its discretion. After determining what those factors should be, FDA will rescind any orders issued under section 519(e) of the act, if the agency determines that tracking is not necessary to protect the public health. The agency has requested comments on the implementation of tracking requirements enacted by FDAMA. After considering the: (1) Agency's experience; (2) information provided by the public at the January 15, 1998, meeting; and (3) written submissions received afterwards, the agency has [[Page 10640]] tentatively identified several products that are subject to the February 1998, tracking orders for which there may be factors that may be considered in the agency's exercise of discretion not to track a particular device, even though it meets the statutory criteria. These devices are the following: Table 2.--Previously ``Mandated'' Devices--Permanently Implanted Devices ------------------------------------------------------------------------ 21 CFR Section Classification ------------------------------------------------------------------------ 870.3450 Vascular graft prosthesis of less than 6 millimeters diameter 870.3460 Vascular graft prosthesis of 6 millimeters and greater diameter (no cite) Interarticular disc prosthesis (interpositional implant) 870.3800 Annuloplasty ring 878.3720 Tracheal Prosthesis (no cite) Arterial stents (used in coronary arteries or peripheral arteries) ------------------------------------------------------------------------ Table 3.--Previously ``Designated'' Devices ------------------------------------------------------------------------ 21 CFR Section Classification ------------------------------------------------------------------------ 876.3350 Penile inflatable implant 878.3530 Silicone inflatable breast prosthesis 878.3540 Silicone gel-filled breast prosthesis 876.3750 Testicular prosthesis, silicone gel-filled (no cite) Silicone gel-filled chin prosthesis (no cite) Silicone gel-filled angel chik reflux device 880.575 Infusion pump (i.e., those designated and labeled for use exclusively for fluids with low potential risks, e.g., enteral feeding, anti- infectives) ------------------------------------------------------------------------ The agency invites comments on these devices, as well as any other devices that should be added or deleted from the list of those devices subject to tracking requirements. III. Comments Interested persons may, by or before May 4, 1998 submit to the Dockets Management Branch (address above) written comments concerning this notice. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. The notice and received comments may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday. Dated: February 25, 1998. D.B. Burlington, Director, Center for Devices and Radiological Health. [FR Doc. 98-5520 Filed 2-27-98; 3:14 pm] BILLING CODE 4160-01-F